Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Losartan Potassium NDC 68071-2690 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
pdp - 68071 2690 3
This is a description of Losartan Potassium 50mg tablets manufactured by NuCare Pharmaceuticals. The NDC number is 68071-2690-3 and the lot number is 00000. The tablets come in a package of 30 with a serial number of 0000000002. The MFR NDC number is 43547-361-03 and the expiration date is 00-00. The label contains instructions on dosage and storage, and includes warning to keep out of reach of children and store at controlled temperature 68-77°F.*
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
The text is describing a comparison between two medications, Atenolol and Losartan Potassium, in terms of their effects on the primary endpoint in a study. The study tracked patients for a period of 66 months and found an adjusted risk reduction of 13% with Losartan Potassium compared to Atenolol. The statistical significance of this finding is reported as p=0.021.*
Figure 2 - spl image3 figure2
This appears to be a comparison of two medications, Atenolol and Losartan Potassium, for their effectiveness in reducing the risk of fatal/non-fatal stroke. The adjusted risk reduction for Losartan Potassium is 25% with a p-value of 0.001. The data is presented in a table showing the percentage of patients with fatal/non-fatal stroke over the course of 66 months.*
Figure 3 - spl image4 figure3
This is a table or figure showing the primary endpoint events, including stroke, fatal/non-fatal, among demographic subgroups, stratified by age, gender, race, ISH, diabetes, and history of CVD, in a study comparing Losartan Potassium and Atenolol. The table also includes the number of events, event rate, hazard ratio, and 95% confidence interval. The symbols are proportional to sample size. The results are adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 - spl image5 figure4
This appears to be a chart representing the percentage of patients with an event, with two groups being compared: one group taking Losartan Potassium, and the other taking a placebo. It appears that after 48 months, 60% of patients taking placebo experienced an event, while 40% of patients taking Losartan Potassium experienced an event. The risk reduction is reported as 16.1% with a significance level of p=0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.